CLX-0921
CLX-0921 is an orally active PPARγ agonist with an IC50 of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 249886-47-3
- 화학식: C28H25NO7S
- 분자량:519.57
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
PPARγ 1.54 μM (IC50) |
CLX-0921 (0.01 M, 0.1 M, 1.0 M, and 10 M) increases glucose uptake in 3T3-L1 adipocytes. CLX-0921 has potent antihyperglycemic activity with low adipogenic potential[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/KsJ-db/db and C57BL/6J-ob/ob mice (7-week-old)[1]
-
Dosage:3.1 mg/kg, 6.3 mg/kg, and 12.5 mg/kg
-
Administration:Oral gavage; once daily; for 19 days
-
Result:Showed dose-dependent antihyperglycemic activity.
Chemical Information
-
CAS No. 249886-47-3
-
분자량 519.57
-
화학식 C28H25NO7S
-
SMILES
O=C(OC)/C(C1=CC=C(OC2=CC=C(CC(SC(N3)=O)C3=O)C=C2)C=C1)=C/C4=CC(OC)=CC(OC)=C4
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)